The world’s first end-to-end solution for global pediatric drug development and clinical trials

More than 60% of drugs used in children are not approved for pediatric use. Why? They have not been successfully tested in pediatric clinical trials. In fact, a recent study found a failure rate of up to 42% for trials that were done under the 2002 Best Pharmaceuticals for Children Act (BPCA).

The FDA and EMA now mandate a pediatric component for most clinical research, and we agree. Pediatric drug development, trial design and execution should be tailored to the needs of children and their families.